Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR2 | Q9NS75 | 9/20 | 0.42 |
| ▸ | CYSLTR1 | Q9Y271 | 9/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4081375 | 0.88 | TRPV1 (0.55) | CYSLTR2CYSLTR1TRPV1MAPT | |
| SCHEMBL4086902 | 0.86 | NR1H4 (0.53) | ROCK2HDAC1MEN1ALDH1A1MAPT | |
| SCHEMBL4085620 | 0.86 | CYSLTR2 (0.42) | CYSLTR2CYSLTR1TRPV1MEN1ALDH1A1 | |
| SCHEMBL4091869 | 0.85 | ABCG2 (0.46) | CYSLTR2CYSLTR1TRPV1MEN1ALDH1A1 | |
| SCHEMBL4086790 | 0.82 | DCUN1D1 (0.42) | CYSLTR2CYSLTR1TRPV1HDAC1 | |
| SCHEMBL4092624 | 0.79 | GCGR (0.53) | — | |
| SCHEMBL4086912 | 0.75 | ROCK2 (0.48) | ROCK2NR1H4 | |
| SCHEMBL4081625 | 0.74 | ALDH1A1 (0.43) | MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL4097734 | 0.74 | GCGR (0.51) | ALDH1A1KMT2ANR1H4 | |
| SCHEMBL4092088 | 0.74 | GCGR (0.47) | MEN1ALDH1A1MAPTKMT2ANR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | NOVO NORDISK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| EP-1183229-B1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK AS (DK) | 2005-10-26 | — | — | EP | disclosed |
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2005-09-15 | — | — | US | disclosed |
| US-6875760-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-04-05 | — | — | US | disclosed |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-11-27 | — | — | US | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | CYSLTR2 2665/4885CYSLTR1 2292/4885ROCK2 2141/4885 |
| US-20090143592-A1 | Glucagon Antagonists/Inverse Agonists | GLP1R, GPR119, GCGR | CYSLTR2 2665/4885CYSLTR1 2292/4885ROCK2 2141/4885 |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | CYSLTR2 2665/4885CYSLTR1 2292/4885ROCK2 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.